Determine the necessary mass, volume, or concentration for preparing a solution.
PCSK9-IN-10 - ≥98% , CAS No.368434-98-4
AVAILABLE TO ORDER
GRADE & PURITY ≥98%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC 50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia.
In Vitro
PCSK9-IN-10 (compound 3s) (0, 2.5, 5, 12.5, 25 µM; 24 h) significantly decreases the PCSK9 protein expression and increases the expression of LDL receptor (LDLR) in a dose dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: HepG2 cells Concentration: 0-1000 µM Incubation Time: 24 h Result: Showed low cytotoxicity to HepG2 cells. Western Blot AnalysisCell Line: HepG2 cells Concentration: 0, 2.5, 5, 12.5, 25 µM Incubation Time: 24 h Result: Significantly decreased PCSK9 protein level in a dose dependent manner.
In Vivo
PCSK9-IN-10 (30 mg/kg; p.o.; once a day for 8 weeks) reduces total cholesterol (TC) and atherosclerotic plaque size in ApoE KO mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Eight weeks old male ApoE KO mice Dosage: 30 mg/kg Administration: P.o.; once a day for 8 weeks Result: Inhibited both hepatic and serum PCSK9 content obviously and reduced reduced atherosclerotic plaque size.
Form:Solid
Specifications
Specifications & Purity
≥98%
Biochemical and Physiological Mechanisms
PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC 50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the poten
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
INHIBITOR
Purity
≥98%
Names and Identifiers
| Molecular Weight | 373.41 |
|---|
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
| Solubility | DMSO : 250 mg/mL (669.51 mM; Need ultrasonic) |
|---|
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.